Speaker illustration

Doctor Robert Giugliano

Brigham and Women's Hospital, Department of Medicine, Cardiovascular Division, TIMI Study Group, Boston (United States of America)

Member of:

European Society of Cardiology

Dr Robert P. Giugliano is a Sr Investigator with the TIMI Study Group, Physician in the CV Division at Brigham and Women’s Hospital, Professor of Medicine at Harvard Medical School, Boston, USA. He graduated summa cum laude, phi beta kappa from Dartmouth College. He received his medical degree at Harvard Medical School. He completed his internship, residency and chief residency at Cedars-Sinai Medical Centre, Los Angeles, USA, and a Cardiology Fellow at Massachusetts General Hospital, USA. His research interests are novel lipid-lowering therapies, antithrombotic therapies for afib and ACS, and assessment of outcomes in patients with ACS. Dr Giugliano has authored more than 300 original articles, 200 reviews/editorials/book chapters, and serves on editorial boards. He is the Principal TIMI Inv for 11 clinical trials including the ENGAGE AF-TIMI 48 trial with edoxaban, EC member of several trials including IMPROVE-IT, FOURIER, VESALIUS-CV, and AZALEA-TIMI 71 trials.

Anticoagulation in elderly atrial fibrillation patients: clinical considerations and unmet needs

Event: ESC CONGRESS 2020 - The Digital Experience

Topic: Prevention

Session type: Industry Q&A session


This platform is supported by

logo Novo Nordisk